FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Trial Inclusion, Exclusion Workshop Report

FDA releases a report summarizing its 4/16 public workshop on clinical trial inclusion and exclusion.

Federal Register

Comments Sought on Sunscreen Info Collection

Federal Register notice: FDA seeks comments on an information collection extension entitled Sun Protection Factor Labeling and Testing Requirements fo...

Federal Register

Draft Guide on Osteoarthritis Structural Endpoints

Federal Register notice: FDA makes available a draft guidance entitled Osteoarthritis: Structural Endpoints for the Development of Drugs, Devices, and...

Federal Register

Members Sought for Device Advisory Panels

Federal Register notice: FDA requests nominations for voting members to serve on the Device Good Manufacturing Practice Advisory Committee and device ...

Federal Register

Danicrine Not Withdrawn Due to Safety/Efficacy

Federal Register notice: FDA determines that Danocrine (danazol) Capsules, 50mg, 100mg, and 200mg, were not withdrawn from sale for reasons of safety ...

Medical Devices

Class 1 Recall of bioMerieux Vitek 2 Test Cards

FDA classifies as Class 1 a bioMerieux recall of its Vitek 2 Gram Positive Antimicrobial Susceptibility Testing Cards due to false results for some st...

Human Drugs

Biocodex Seizure Drug Approved by FDA

FDA approves a Biocodex SAS NDA for Diacomit (stiripentol) for treating seizures associated with Dravet syndrome in patients two years of age and olde...

Medical Devices

FDA Approves Roches Test for Iressa

FDA approves Roches cobas EGFR Mutation Test v2 as a companion diagnostic test for selecting patients suitable for AstraZenecas Iressa (gefitinib) in ...

Human Drugs

FDA Approves Kala Eye Pain Drug

FDA approves a Kala Pharmaceuticals NDA for Inveltys (loteprednol etabonate ophthalmic suspension) 1% for treating post-operative inflammation and pai...

Human Drugs

Mallinckrodt Stannsoporfin Complete Response Letter

FDA issues a complete response letter with recommendations for resubmitting Malinckrodys NDA for stannsoporfin.